| Cash flow (USD) | Q2 2026 ended Jun 30, 2026 | Q1 2026 ended Mar 31, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 30, 2025 | Q2 2025 ended Jun 30, 2025 | Q1 2025 ended Mar 31, 2025 | Q4 2024 ended Dec 31, 2024 | Q3 2024 ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Net income | 907.00M | 1.34B | 672.00M | 755.00M | 797.00M | 674.00M | 565.00M | 469.00M |
| Depreciation and amortization | 355.00M | 351.00M | 365.00M | 117.00M | 111.00M | 325.00M | 348.00M | 102.00M |
| Stock-based compensation | 87.00M | 83.00M | 71.00M | 79.00M | 75.00M | 74.00M | 69.00M | 68.00M |
| Cash from operations | 1.47B | 348.00M | 1.36B | 1.34B | 1.29B | 541.00M | 1.46B | 1.00B |
| Capital expenditure | -195.00M | -177.00M | -351.00M | -181.00M | -157.00M | -187.00M | -277.00M | -179.00M |
| Free cash flow | 1.28B | 171.00M | 1.01B | 1.16B | 1.13B | 354.00M | 1.18B | 823.00M |
| Acquisitions | -195.00M | -523.00M | -89.00M | -256.00M | -1.01B | -239.00M | -3.42B | -1.13B |
| Cash from investing | -1.96B | -591.00M | -512.00M | -502.00M | -1.13B | -500.00M | -3.70B | -1.43B |
| Dividends paid | 0 | 0 | ||||||
| Cash from financing | -410.00M | -260.00M | -184.00M | -104.00M | -340.00M | 233.00M | 214.00M | 7.00M |
| Net change in cash | -890.00M | -504.00M | 671.00M | 735.00M | -179.00M | 314.00M | -2.04B | -412.00M |
From Boston Scientific's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.